Literature DB >> 6426080

The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.

E J Brommer, F H Derkx, M M Barrett-Bergshoeff, M A Schalekamp.   

Abstract

We tested the response of the fibrinolytic activity and factor VIII-antigen levels to infusion of DDAVP in healthy volunteers and we studied the influence of propranolol and aspirin on this response. After DDAVP, 0.4 microgram/kg in 10 min i.v., the fibrinolytic activity of redissolved euglobulins rose from 179 to 452 mm2 (lysis area of fibrin plates); after pretreatment with propranolol, 320 mg per day during 7 days, DDAVP induced a similar rise (from 166 to 471 mm2) and after pretreatment with a single dose of aspirin, 600 mg, ingested 5 hr before the DDAVP infusion, the lysis area increased from 159 to 455 mm2. Factor VIII-antigen level increased within 60 min after DDAVP from 104 to 208%; after pretreatment with propranolol from 111 to 230% and after a single dose of aspirin, DDAVP induced a rise from 107 to 206%. From these data we conclude that neither baseline levels nor the release of plasminogen activator or factor VIII after DDAVP infusion are influenced by beta-blockade or by interference with prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426080

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

Review 1.  Lifestyle, fibrinolysis and lipids.

Authors:  E J Brommer; J A Gevers Leuven; P Brakman
Journal:  Pharm World Sci       Date:  1997-04

2.  Efficacy and Safety of Low-Dose Streptokinase plus Desmopressin in Acute Myocardial Infarction: A Pilot Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Flushing and haemodynamic responses to vasopressin peptides in the rhesus monkey.

Authors:  D P Brooks; P F Koster; F L Stassen; C R Albrightson; W F Huffman; M A Wasserman; L B Kinter
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.